Latest Advances in Lung Cancer Research

A new targeted therapy produced a 94% response rate in ROS1-positive lung cancer, with strong results even against brain metastases.

Patients with ROS1 lung cancer have a new option. On July 22, 2026, the FDA approved zidesamtinib, sold as Jideytro. The maker is Nuvalent, Inc.

A new lung cancer drug is making headlines. At the 2026 ASCO meeting, researchers shared exciting results for a drug called ivonescimab. In a large study, it lowered the risk of death by 34% for people with a hard-to-treat type of lung cancer.

New data shows elisrasib provides strong, lasting tumor responses for advanced lung cancer patients, including those who failed previous KRAS-targeted treatments.

New pill sevabertinib (Hyrnuo) shrinks tumors in 70% of patients with rare HER2-mutated lung cancer. Learn about this FDA fast-tracked breakthrough.

Dr. Ross Camidge shares clinical insights and personal reflections on the evolution of lung cancer research and the vital importance of innovation in targeted therapies.

The FDA has fully approved the drug tarlatamab (Imdelltra) for small-cell lung cancer, after a trial showed it reduces death risk by ~40% compared with chemo.

The FDA has approved a new drug called Datroway (datopotamab deruxtecan) for patients with EGFR-positive non-small cell lung cancer (NSCLC) who have already tried targeted therapy and chemotherapy. This approval marks an important step forward in lung cancer treatment.

Clinical cancer informatics research applying computational methods or digital health technologies to improve cancer care and patient outcomes.

Researchers repurposed MDM2 inhibitor RG7388 as a potential targeted therapy for treating TP53-mutant non-small cell lung cancer patients.

Dr. Ramalingam emphasizes community oncologists must prioritize molecular testing and lung cancer screening to improve patient access to treatments.